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Study design: The study design of this paper is a systematic review of literature published in the recent 10 years.
Objective: It is the objective of this paper to compare the clinical efficacy and safety of minimal access (MIS) spinal
surgery and open spinal surgery for treating painful spine metastasis.
Methods: Two research questions below were determined through a consensus among a panel of spine experts.
A systematic review of literature on spinal surgery was conducted by searching PubMed with a combination of
keywords including “metastatic”, “metastasis”, “metastases”, “spinal”, and “spine”. Independent reviewers selected the
articles for analysis after screening the titles, abstracts, and full texts, then extracted data and graded the quality of
each paper according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)
criteria. Specific clinical questions were as follows:
1. In patients with spine metastatic disease, what is the impact of different surgical approaches (MIS versus open)
on pain relief and functional outcome?
2. In patients with metastatic disease, what is the impact of different surgical approaches (MIS versus open) on
local recurrence, survive rate, and complication?
Results: A total of 1,076 abstracts were identified using various keywords. 5 prospective (level II) and 12
retrospective articles (level III) were eligible for inclusion, involving a total of 979 cases of spine metastasis. There
were 345 cases in 8 studies regarding the clinical evaluation of MIS spinal surgery and 634 cases in 9 studies
regarding the clinical evaluation of open spinal surgery for spine metastasis.
Conclusion: Both open spinal surgery and MIS seem to achieve the improvement of pain and neurological
dysfunction through decompression and stabilization for patients with spine metastasis, but open surgery may
involve more major complications with a trend of lower survival rates and higher recurrence rates compared
to MIS.
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Introduction
About 10% of cancer patients develop metastases in the
spine [1]. The most common site of metastasis in the
spine is the thoracic spine (50% to 60% of all metasta-
ses), followed by the lumbar (30% to 35%) and cervical
spines (10% to 15%) [2-4]. Vertebral metastasis is one of
the most serious life-threatening diseases [5]. About one
third of patients with spinal metastases become symp-
tomatic, which means intractable pain, neurological defi-
cits, and/or biomechanical instability requiring surgical
treatment [3,6].
These nonsurgical methods, such as chemotherapy,
radiotherapy, and hormonal therapy, were commonly
used for the management of vertebral metastatic disease,
which have been proven to be effective in halting the
osteolytic process and reversing the neurological com-
promise [7]. However, these modalities are unable to
provide stability to an instable spinal column and also
unable to be expected to relieve pain and spinal cord
compression. In these cases, surgery is the best method
for the resolution of intractable pain, neurological com-
promise, and overt or impending spinal instability in pa-
tients with spinal metastases. The primary goal of the
surgery is to improve patients’ quality of life by provi-
ding pain relief, maintaining or improving neurological
function, and restoring the structural integrity of the spi-
nal column [8].
Stabilization of the spine is often necessary as exten-
sive lesions may cause spinal instability by erosion of
the normal bony structures. The most efficacious ther-
apy for restoring spinal instability is reconstructive sur-
gical intervention. Unfortunately, lots of patients are
not considered as candidates for conventional surgery
intervention due to neoplasm-associated comorbidities
such as malnourishment and a weak immune system
that make amounts of surgical procedures unfeasible
[9]. However, these patients can be managed with verte-
bral augmentation, since it can provide some degree of
restabilization [10].
Vertebroplasty or kyphoplasty, which involves the per-
cutaneous injection of polymethyl methacrylate (PMMA)
bone cement into a collapsed vertebral body, is a cur-
rently available minimally invasive spine surgery for pallia-
tive treatment. Poor surgical candidates with disabling
pain secondary to a pathologic thoracic or lumbar ver-
tebral body fracture without epidural compression are
ideal candidates for these procedures [11]. The two proce-
dures have been shown to relieve pain effectively to im-
prove the quality of life, and they can be used as effective
palliative treatment even for patients whose general
condition is quite poor, with decreased pain, less blood
loss, and shorter hospital stays [12]. On the other hand,
their putative benefits with regard to spinal stabilityand neurological function, as well as their risks affect-
ing their overall survival, have not yet been adequately
documented by clinical studies because of limitations
such as insufficient spinal cord decompression and sta-
bilizing the vertebral column.
Despite numerous reports on open spinal surgery in
treating painful spine metastasis, there exist no ran-
domized controlled comparisons of clinical efficacy and
safety between open and minimal access (MIS) proce-
dures. In addition, due to the heterogeneity of study de-
signs, inconsistent reporting of complications, and the use
of different grading scales for pain and functional out-
comes, it was not possible to perform a meta-analysis
using the prospective and retrospective studies. There-
fore, we endeavored to perform a quantitative system-
atic review of the current literature published in the
recent 10 years to evaluate the clinical efficacy between
MIS and open spinal surgery in patients with spinal
metastases. A secondary aim was to compare complica-
tion rates between MIS and open spinal surgery.
Materials and methods
Two clinically relevant questions below were determined
through a consensus among a panel of spine oncology
experts (the Spine Oncology Study Group), and a sys-
tematic review of related literature published in the re-
cent 10 years was conducted using PubMed. Specific
clinical questions were as follows:
1. In patients with metastatic disease, what is the
impact of different surgical approaches (MIS
versus open) on alterations of pain and neurologic
function?
2. In patients with metastatic disease, what is the
impact of different surgical approaches (MIS versus
open) on local recurrence, survive rate, and
complication?
Search criteria
We used the search terms that included “spin*”, “metasta*”,
and “surg*” to searched literature from PubMed. The
following terms would be contained: “metastatic”, “me-
tastasis”, “metastases”, “spinal”, “spine”, “surgery”, and
“surgical”.
Criteria for possible inclusion are as follows: 1) arti-
cles published in the recent 10 years, 2) all articles in
English or with an English translation, 3) articles with
20 or more subjects, 4) adult age group (18 years and
older), 5) articles describing surgical treatment of spinal
metastatic cancer, and 6) articles evaluating the alter-
ations of pain and neurologic function postoperatively.
Exclusion criteria include the following: 1) primary tu-
mors, 2) intradural tumors, 3) pediatric age group, 4)
articles with fewer than 20 subjects, and 5) articles with
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tumors in the same series).
Studies were reviewed using a standardized data col-
lection form. The type of study (prospective or retro-
spective) was noted. Data including surgery technique,
the total number of patients, and the type of tumors
were totally collected. The methods of pre- and postop-
erative clinical evaluations with respect to pain and
functional outcome were also recorded. All temporary
and permanent complications were collected, including
major and minor complications. To avoid duplicate re-
cords of patients’ data, each group or institution was lim-
ited to one study in the systematic review. Some authors
were contacted directly to clarify certain aspects of their
studies.
The quality of evidence for each article was evaluated
as high, moderate, low, or very low. The results of the
systematic review and ratings of the evidence for each
article were determined by a multidisciplinary, inter-
national group of spine oncology surgeons, oncologists,
and methodologists (Spine Oncology Study Group). The
group then went through a consensus-based decision-
making process using a modified Delphi technique to ar-
rive at treatment recommendations related to the key
clinical questions. This process and the strength of thePotentially relevant stu
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Figure 1 Flow diagram showing identification of studies included in trecommendation were based on the Grading of Recom-
mendations, Assessment, Development, and Evaluation
(GRADE) method [13,14]. These articles were evaluated
independently by the authors according to the GRADE
criteria.
Result
A total of 1,076 abstracts were identified using various
keywords. All abstracts were screened, and 1,013 articles
were excluded as obviously unrelated. The full texts of
63 papers were screened and 17 papers were identified
to meet the inclusion criteria, including 5 prospective
(level II) [15-19] and 12 retrospective articles (level III)
[20-31] involving 979 cases of spine metastasis. The de-
tails of article selection were presented in Figure 1.
There were 345 cases in 8 studies regarding the clinical
evaluation of MIS spinal surgery and 634 cases in 9
studies regarding the clinical evaluation of open spinal
surgery for spine metastasis (Table 1). In one study, the
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Table 1 Characteristics of included studies
Study Year Type of study Quality Number of
Patients
Mean age Procedure Primary Outcome Follow-up
Minimal
Pizzoli et al. [20] 2009 Retrospective Very low 39 NA PVP with PMMA Mixed VAS, mobility, analgesic use NA
Chen et al. [21] 2009 Retrospective Very low 31 67 PVP with PMMA Mixed VAS, Karnofsky scale 12 months
Qian et al. [22] 2011 Retrospective Very low 48 68.5 Kyphoplasty Mixed VAS, ODI, SF-36, vertebral body
height variation
24 months
Farrokhi et al. [15] 2012 Prospective Very low 25 53.5 PVP with PMMA Mixed VAS NA
Tseng et al. [23] 2008 Retrospective Very low 57 65.18 PVP with PMMA Mixed VAS, amounts of nonnarcotic
and narcotic analgesic
6 months
Yang et al. [16] 2009 Prospective Very low 40 57.63 PVP with PMMA Mixed VAS, KPS 1 year
Pflugmacher et al. [17] 2008 Prospective Very low 65 66 Balloon kyphoplasty Mixed VAS, ODI 24 months
Anselmetti et al. [18] 2013 Prospective Very low 40 66.8 PVP with PEEK Mixed VAS, ODI 10 months
Open
Holman et al. [24] 2005 Retrospective Very low 139 55 Posterior/anterior/combined tumor resection,
decompression, instrumentation, fusion
Mixed VAS, Frankel grades 12 months
Chong et al. [25] 2012 Retrospective Very low 105 58.3 Single-stage posterior decompression
and stabilization
Mixed VAS, Frankel grade, KPS 48 months
Eid et al. [26] 2011 Retrospective Very low 45 53 Circumferential decompression and fusion
by means of PTA
Mixed VAS, ASIA grades 13 months
Liang et al. [27] 2013 Retrospective Very low 92 NA Posterior/anterior/combined tumor resection,
decompression, instrumentation, fusion
Mixed VAS, Frankel grades, Karnofsky
score, Tokuhashi scores
22 months
Wonik Cho et al. [28] 2012 Retrospective Very low 46 56.4 ACF, ACF and PF, DLF, DL Mixed VAS, JOAS, Tomita score 39 months
Walter et al. [29] 2012 Retrospective Very low 57 58.6 Posterolateral approach for decompression
combined with posterior instrumentation
Mixed VAS, Frankel grades, ECOG
grades, TPS
46 months
Dae-Chul Cho et al. [30] 2009 Retrospective Very low 21 56.6 Posterolateral transpedicular approach with
posterior instrumentation
Mixed VAS, Frankel grades, and
ECOG grades
13 months
Shehadi et al. [31] 2007 Retrospective Very low 87 53 Posterior/anterior/combined tumor resection,
decompression, instrumentation, fusion
Breast cancer VAS, Frankel grades 13 months
Street et al. [19] 2007 Prospective Very low 42 56.04 Single-stage posterolateral vertebrectomy Mixed VAS, ECOG grading NA
PVP percutaneous vertebroplasty, PMMA polymethyl methacrylate, PEEK polyetheretherketone, VAS visual analog scale, ODI Oswestry Disability Index, JOAS Japanese Orthopaedic Association Score, KPS Karnofsky
performance scores, ASIA American Spinal Injury Association, ECOG Eastern Cooperative Oncology Group, PTA posterolateral transpedicular approach, TPS Tomita’s prognostic score, ACF anterior corpectomy and fusion,
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nal surgery were performed primarily with vertebro-
plasty whereas two studies [22,17] were performed with
kyphoplasty.
Pain alleviation was crucially important for the therapy
of spine metastases to improve quality of life in patients.
A visual analog scale was available for each study to
evaluate the effect of pain relief in patients with spine
metastases. In all, one study did not display the visual
analog scale (VAS) score in detail [26], and prospective
studies had especially detailed pre- and postoperative
VAS score. It was found that both MIS and open spinal
surgery were efficient in pain alleviation, and most of
the studies reported statistically significant improvement
(Table 2).Given the high rates of pain alleviation, the re-
sults suggest that both MIS and open spinal surgery are
efficacious in respect to pain alleviation through decom-
pression and stabilization.
Each study assessed postoperative neurologic function,
and multiple methods for evaluating neurologic function
were included, such as the Eastern Cooperative Oncology
Group performance scale, the Oswestry Disability Index,
the Frankel scale, the Karnofsky scale and American
Spinal Injury Association grades, the Short Form 36Table 2 VAS scores in included studies
Study Pre Post
Minimal
Pizzoli et al. [20] 8.62 (±0.71) 2.84 (±1.36)
Chen et al. [21] 8.9 (±0.93) 2.6 (±1.71)
Qian et al. [22] 7.4 (±2.1) 3.8 ( ±1.6)
3.2 (±1.0)
Farrokhi et al. [15] 8.23 (NA) 2.12 (NA)
1 (NA)
Tseng et al. [23] 8.1 (±0.67) 3.8 (±1.9)
2.8 (±2.0)
Yang et al. [16] 8.78 (±0.54) 5.41 (±0.94)
Pflugmacher et al. [17] 8.3 (±15) 3.3 (±9)
Anselmetti et al. [18] 10 (±1) 1 (±0.75)
Open
Holman et al. [24] 7 (NA) 2 (NA)
Chong et al. [25] 6.5 (±1.7) 3.4 (±1.6)
Eid et al. [26] NA NA
Liang et al. [27] 6 (NA) 2 (NA)
Wonik Cho et al. [28] 7.86 (±1.05) 4.48 (±2.09)
Walter et al. [29] 6.9 (±1.6) 3.1 (±1.0)
Dae-Chul Cho et al. [30] 6.82 (±2.13) 3.61 (±1.01)
Shehadi et al. [31] 6 (NA) 2 (NA)
Street et al. [19] 7.94 (NA) 4.3 (NA)Physical Function, the Japanese Orthopaedic Association
Score, and the Karnofsky performance scores. The neuro-
logic function was not assessed in two studies (Farrokhi
et al. [15] and Tseng et al. [23]) regarding MIS surgery.
Only nine studies provided pre- and postoperative neu-
rologic function score, and neurologic function was sta-
tistically significantly improved (Table 3). Other studies
without detailed data also showed that MIS and open
spinal surgery were successful in improving physical
function.
It is reported that decreased complication rates are
considered to be one of the advantages of MIS spinal
surgery. This was confirmed by the evidences we pro-
vided in this systematic review. There are no major com-
plications for MIS spinal surgery except in two studies
[20,23], whereas six studies regarding open spinal sur-
gery reported major complications with a trend of lower
survive rates and higher recurrence rates (Table 4).
Discussion
For most of the patients with spinal metastasis, the treat-
ment is largely palliative and aims to achieve relief of pain
and regain function, thus improving the quality of the
life of the patients. Because of the immunocompromisedP value Follow-up Pain relief rate
NA 24 h 98%
P < 0.001 NA 94%
P < 0.001 24 h NA
P < 0.001 6 months NA
P ≤ 0.05 24 h NA
P ≤ 0.05 2 months NA
P < 0.015 24 h NA
P < 0.001 6 months NA
P = 0.032 6 months 95.00%
P < 0.0001 3 months NA
P < 0.001 1 month 100.00%
P < 0.001 1 month 94%
NA 2 weeks NA
NA 1 month 96%
P < 0.001 12 months 90%
P = 0.001 NA NA
P < 0.001 1 month 87.70%
NA 1 month NA
P < 0.001 1 month NA
P < 0.001 NA NA
Table 3 Neurologic function evaluation in included studies
Study Method Scale best to worst Functional outcome P value
Minimal
Pizzoli et al. [20] Mobility 1 to 4 Preoperative: 3.25 ± 0.59, postoperative: 1.24 ± 0.64 P < 0.001
Chen et al. [21] Karnofsky scale 100 to 0 Preoperative: 50 ± 10.65, postoperative: 70 ± 3.59 NA
Qian et al. [22] ODI 0 to 100 Preoperative: 71.5 ± 16.7, postoperative: 29.5 ± 10.2 P < 0.001
SF-36 100 to 0 Preoperative: 34.3 ± 10.8, postoperative: 54.5 ± 10.5 P < 0.05
Yang et al. [16] Karnofsky scale 100 to 0 Preoperative: 69.4 ± 8.3, postoperative: 80.3 ± 7.2 P = 0.002
Pflugmacher et al. [17] ODI 0 to 100 Preoperative: 81 ± 8, postoperative: 39 ± 7 P < 0.0001
Anselmetti et al. [18] ODI 0 to 100 Preoperative: 82.2, postoperative: 4.1 P < 0.001
Open
Holman et al. [24] Frankel grade E to A 46/112 (41%) improved at least one Frankel grade, 20/112
(18%) regained ambulation, seven (5%) worsened
P < 0.05
Chong et al. [25] Frankel grade E to A 21/105 (20%) improved at least one Frankel grade, 21/105
(48%) regained ambulation, 6/105 (5.7%) worsened
P < 0.05
Eid et al. [26] ASIA grade E to A 23/45 (51%) improved one or more grades, 6/45 (20%)
retained their preoperative grade, one (3%) experienced
worsening
P > 0.05
Liang et al. [27] Karnofsky scores 100 to 0 The median postoperative Karnofsky scores increased
from 60 (range, 40 to 80) to 70 (range, 0 to 80)
P < 0.001
Frankel grade E to A 78% improved 1.2 grades at average NA
Wonik Cho et al. [28] JOAS 10 to 0 Preoperative: 13.11 ± 2.75, postoperative: 15.17 ± 2.09 P = 0.001
Walter et al. [29] Frankel grade E to A 13 (22.8%) patients improved, 43 (75.5%) had a stable
neurological status, one single patient (1.8%) experienced
worsening
NA
ECOG grade 0 to 5 Preoperative: 2.0 ± 1.1, postoperative: 1.7 ± 1.3 P < 0.05
Dae-Chul Cho et al. [30] Frankel grade E to A 7/22 (33.3%) improved, 14/21 (66.7%) had a stable
neurological status
NA
ECOG grade 0 to 5 8 had an improved ECOG grade, and 12 showed no change,
1 experienced worsening
NA
Shehadi et al. [31] Frankel grade E to A 85% maintained or improved their Frankel scores NA
Street et al. [19] ECOG grade 0 to 5 Preoperative: 2.5 ± 1.0, postoperative: 1.6 ± 0.75 NA
ODI Oswestry Disability Index, Japanese Orthopaedic Association Score, ECOG Eastern Cooperative Oncology Group, NA not available, SF-36 Short Form 36
Physical Function.
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many patients with spinal metastasis cannot tolerate the
curative surgical methods. In recent years, more and
more minimally invasive spinal interventions are rea-
sonable alternatives to open spinal surgery for treating
spinal metastatic tumors. These procedures can con-
tribute to less soft tissue trauma, lower blood loss, and
shorter hospitalization time. MIS spinal surgery rarely
interferes with the adjuvant treatments. The overall
morbidity is considerably lower in comparison to con-
ventional spine surgery.
Despite this evolution, questions surrounding the ef-
fectiveness of MIS and its comparability to open spinal
surgery in terms of pain and neurologic function remain
unanswered. A direct comparison of clinical efficiency
and safety between open and MIS spinal surgery for spi-
nal metastasis has never been conducted. Given the lackof comparison studies, we aimed to compare the effect
of pain alleviation and functional improvement between
open and MIS spinal surgery by reviewing published
studies in a quantitative manner. Our results suggest
that open or MIS spinal surgery is likely to achieve the
improvement in pain and neurological dysfunction for
spinal metastasis, but open surgery seems to involve
more major complications with a trend of lower sur-
vival rates and higher recurrence rates compared to
MIS surgery.
There are few comparison studies between MIS and
open spinal surgery. Huang et al. [32] performed a direct
retrospective comparison of MOT, MBL, LOS, and CR
for MIS versus open spinal surgery for thoracic spine
metastasis, and no significant difference was found. How-
ever, the amount of patients requiring at least a 2-day ad-
mission in the open group was significantly larger than
Table 4 Serious complications in included studies (excluding deaths)
Study Recurrence Survival Complications
Minimal
Pizzoli et al. [20] 5.1% NA Three major complications (one pneumothorax and
two symptomatic leakages) (2.8%), two minor
complications (cement pulmonary embolism) (1.8%)
Chen et al. [21] NA 74% at 6 months, 39% at 12 months No major complication
Qian et al. [22] No 81% at 2 years No major complications, cement leakage (18.6%)
Farrokhi et al. [15] NA NA Cement leakage (44%)
Tseng et al. [23] NA Two patients died during hospitalization Cement extravasation (17.9% minor extravasation,
3.9% major extravasation)(21.8%)
Yang et al. [16] No 80.0% at 1 year Seven paravertebral cement leakage (17.5%)
Pflugmacher et al. [17] 80.0% at 1 year, 66% at 2 years Cement leakage (12.1%), adjacent incident
fracture (8%)
Anselmetti et al. [18] 20% 85% at 3 months Cement leakage (16.3%)
Open
Holman et al. [24] 8% Mean survival was 14.8 months, 67% at
0.5 months, 54% at 1 month, 23% at 5 years
Major complications (18%) and minor
complications (21%)
Chong et al. [25] NA Median survival was 6.0 months, 34% at
1 year, 14% at 2 years survival rates
Surgical complications occurred in patients (10%),
no mechanical failure
Eid et al. [26] No Mean survival was 13 months Unstable (15.5%), wound infection (15.5%),
hematoma (4%) and deep vein thrombosis (2%)
Liang et al. [27] NA The median survival was 15 months, 61% at
1 year, and 35% at 3 years
Major complications (23%)
Wonik Cho et al. [28] 39.10% Mean survival was 11.82 months, 44.4% at
6 months, 35.6% at 12 months, and 19.0% at
24 months
Two operation site infection, two pneumonia, one
esophageal fistula after anterior approach (10.9%)
Walter et al. [29] 1.70% Mean survival was 11.4 months, 42.1% at
1 year
Superficial wound infections and one seroma (5.3%)
Dae-Chul Cho et al. [30] 14% Mean survival was 8.9 months One wound infection and one wound dehiscence
(9.5% )
Shehadi et al. [31] 11.50% Median survival was 21 months, 62% at 1 year,
33% at 3 years, and 24% at 5 years
Major complications by surgical approach (17%)
Street et al. [19] 2.30% 75% at 6 months and 50% at 12 months Major complications (26%)
NA not available.
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there is truth that there is no significant difference in
the functional outcome between the MIS and open
group, the possible reason is that the potential benefit
of MIS is counteracted by the more complicated nature
of patients with metastatic spine disease during operation
[33]. Payer et al. [34] also demonstrated that mean blood
loss, operative time, and complication rates in spinal
tumor patients were higher than that of the fracture pa-
tients with anterior approach.
Conclusions
In conclusion, we performed the systematic review based
on literature published in the recent 10 years to possibly
compare clinical efficiency and complication rate bet-
ween open and MIS spinal surgery for spine metastasis
and found that both open spinal surgery and MIS seemto achieve the improvement of pain and neurological
dysfunction through decompression and stabilization,
but open surgery may involve more major complications
with a trend of lower survival rates and higher recur-
rence rates compared to MIS. However, it is necessary to
perform a controlled study to compare the clinical effi-
ciency between the two procedures for spine metastasis
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